Dextromethorphan/bupropion modulated delivery tablet shows significant improvement in patient-reported outcomes in major depressive disorder

RCT (n=327) showed statistically significant improvement in patient-reported depressive symptoms as measured by the QIDS-SR-16 total score (53% on dextromethorphan/bupropion (NMDA receptor antagonist combination) vs. 33% on placebo;p<0.001), at 16 weeks.

Source:

Biospace Inc.